Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Deffered Revenue: 2015-2024

Historic Non-Current Deffered Revenue for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $18.3 million.

  • Intellia Therapeutics' Non-Current Deffered Revenue fell 44.53% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 44.53%. This contributed to the annual value of $18.3 million for FY2024, which is 53.01% down from last year.
  • As of FY2024, Intellia Therapeutics' Non-Current Deffered Revenue stood at $18.3 million, which was down 53.01% from $38.9 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Non-Current Deffered Revenue registered a high of $63.5 million during FY2021, and its lowest value of $18.3 million during FY2024.
  • Over the past 3 years, Intellia Therapeutics' median Non-Current Deffered Revenue value was $19.9 million (recorded in 2022), while the average stood at $25.7 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Non-Current Deffered Revenue surged by 218.46% in 2020, and later tumbled by 68.60% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $51.4 million in 2020, then grew by 23.53% to $63.5 million in 2021, then tumbled by 68.60% to $19.9 million in 2022, then soared by 94.93% to $38.9 million in 2023, then crashed by 53.01% to $18.3 million in 2024.